Ethnic differences in total and HDL cholesterol among Turkish, Moroccan and Dutch ethnic groups living in Amsterdam, the Netherlands

Ujcic-Voortman, Joanne K.; Bos, Griët; Baan, Caroline A.; Uitenbroek, Daan G.; Verhoeff, Arnoud P.; Seidell, Jacob C.
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p740
Academic Journal
Background: High total cholesterol and low HDL (high-density lipoprotein) cholesterol are important determinants of cardiovascular disease. Little is known about dyslipidemia among Turkish and Moroccan migrants, two of the largest ethnic minority groups in several European countries. This study examines ethnic differences in total and HDL cholesterol levels between Dutch, Turkish and Moroccan ethnic groups. Methods: Data were collected in the setting of a general health survey, in Amsterdam, the Netherlands, in 2004. Total response rate was 45% (Dutch: 46%, Turks: 50%, Moroccans: 39%). From 1,220 adults information on history of hypercholesterolemia, lifestyle and demographic background was obtained via health interviews. In a physical examination measurements of anthropometry and blood pressure were performed and blood was collected. Total and HDL cholesterol were determined in serum. Results: Total cholesterol levels were lower and hypercholesterolemia was less prevalent among the Moroccan and Turkish than the Dutch ethnic population. HDL cholesterol was also relatively low among these migrant groups. The resulting total/HDL cholesterol ratio was particularly unfavourable among the Turkish ethnic group. Controlling for Body Mass Index and alcohol abstinence substantially attenuated ethnic differences in HDL cholesterol levels and total/HDL cholesterol ratio. Conclusions: Total cholesterol levels are relatively low in Turkish and Moroccan migrants. However part of this advantage is off-set by their relatively low levels of HDL cholesterol, resulting in an unfavourable total/HDL cholesterol ratio, particularly in the Turkish population. Important factors in explaining ethnic differences are the relatively high Body Mass Index and level of alcohol abstinence in these migrant groups.


Related Articles

  • HDL Therapy for the Treatment of Cardiovascular Diseases. Parolini, Cinzia; Marchesi, Marta; Chiesa, Giulia // Current Vascular Pharmacology;Oct2009, Vol. 7 Issue 4, p550 

    High-density lipoprotein (HDL) therapy is an emerging area of therapeutic development in the cardiovascular field, aimed at supplementing and improving the vascular benefit exerted by current treatments. Several studies have clearly established that HDL-cholesterol (HDL-C) levels are a potent...

  • Non-HDL-C and total cholesterol/HDL-C best predictors of heart health.  // Contemporary OB/GYN;Sep2005, Vol. 50 Issue 9, p16 

    Discusses research being done on the efficacy of non-high-density lipoprotein cholesterol (non-HDL-C) and the ratio of total cholesterol to HDL-C as predictors of future cardiovascular events. Reference to a study by P. M. Ridker and colleagues published in a 2005 issue of the "Journal of the...

  • Emerging therapeutic strategies to enhance HDL function.  // Lipids in Health & Disease;2011, Vol. 10 Issue 1, p175 

    The article cites a research study that examines the role of high-density lipoproteins (HDL) in the treatment of cardiovascular disease (CVD). Reverse cholesterol transport (RCT) is thought to be the most relevant cardioprotective mechanism mediated by HDL. The development of promising agents...

  • HDL as a target in the treatment of atherosclerotic cardiovascular disease. Linsel-Nitschke, Patrick; Tall, Alan R. // Nature Reviews Drug Discovery;Mar2005, Vol. 4 Issue 3, p193 

    Lipid abnormalities are among the key risk factors for cardiovascular disease. Indeed, lipid-modifying drugs-in particular, the statins, which primarily lower plasma levels of low-density lipoprotein (LDL) cholesterol-considerably reduce the risk of cardiovascular events, leading to their...

  • When good cholesterol goes bad. Fogelman, Alan M. // Nature Medicine;Sep2004, Vol. 10 Issue 9, p902 

    Reports on research concerning the high density lipoprotein (HDL) cholesterol. Occurrence of heart attacks and strokes in persons with perfectly normal cholesterol levels; Role of HDL in patients with cardiovascular disease; Examination of proinflammatory or dysfunctional HDL.

  • High Density Lipoprotein and it's Dysfunction. Eren, Esin; Yilmaz, Necat; Aydin, Ozgur // Open Biochemistry Journal;2012, Vol. 6, p78 

    Plasma high-density lipoprotein cholesterol(HDL-C) levels do not predict functionality and composition of high-density lipoprotein(HDL). Traditionally, keeping levels of low-density lipoprotein cholesterol(LDL-C) down and HDL-C up have been the goal of patients to prevent atherosclerosis that...

  • Implementation Strategies to Improve Non-HDL-Cholesterol Goal Attainment. Virani, Salim S. // Texas Heart Institute Journal;2012, Vol. 39 Issue 2, p228 

    The article discusses the strategies for improving non-high-density-lipoprotein cholesterol (non-HDL-C) goal attainment. It was suggested that non-HDL-C is a better cardiovascular risk marker compared with low-density-lipoprotein cholesterol (LDL-C). The reasons for lower non-HDL-C goal...

  • Torcetrapib: A new strategy to raise HDL cholesterol levels. Bhardwaj, R.; Bhardwaj, P. // Indian Journal of Pharmacology;Feb2005, Vol. 37 Issue 1, p46 

    The article presents a new strategy to raise high-density lipoprotein (HDL) cholesterol levels. HDL cholesterol constitutes a common lipid abnormality in coronary heart disease patients. Agents that increase the HDL cholesterol level are inhibitors of cholesteryl ester transfer protein (CETP)...

  • Atherogenic Lipid Phenotype in a General Group of Subjects. Van, Joanne; Pan, Jianqiu; Charles, M. Arthur; Krauss, Ronald; Wong, Nathan; Xiaoshan Wu // Archives of Pathology & Laboratory Medicine;Nov2007, Vol. 131 Issue 11, p1679 

    Context.—The atherogenic lipid phenotype is a major cardiovascular risk factor, but normal values do not exist derived from 1 analysis in a general study group. Objective.—To determine normal values of all of the atherogenic lipid phenotype parameters using subjects from a general...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics